With data on lead drug, Kadmon and CEO Waksal plot their redemption

With data on lead drug, Kadmon and CEO Waksal plot their redemption

STAT Plus: With strong data on lead drug, Kadmon and CEO Harlan Waksal plot their redemption

By ADAM FEUERSTEIN

HYACINTH EMPINADO/STAT

The New York-based biotech, which is developing the first drug designed specifically to target chronic GVHD, was in disarray when Harlan Waksal took over.

READ MORE